• Home Dutch
  •  EN 
  • Employee login

Publications 2015

  1. Aarnoutse RE, Sturkenboom MG, Robijns K, Harteveld AR, Greijdanus B, Uges DR, Touw DJ, Alffenaar JW. An interlaboratory quality control programme for the measurement of tuberculosis drugs. Eur Respir J. 2015 Jul;46(1):268-71.
  2. Alffenaar JW, Bolhuis M, van Hateren K, Sturkenboom M, Akkerman O, de Lange W, Greijdanus B, van der Werf T, Touw D. Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother. 2015 Sep;59(9):5675-80.
  3. Alffenaar JW, Gumbo T, Aarnoutse R. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2015 Feb 5;372(6):576.
  4. Alffenaar JWC, Akkerman OW, Bolhuis MS, Boeree MJ, de Lange WCM, van der Werf TS. Breakpoints and drug exposure are inevitably closely linked. Antimicrobial Agents and Chemotherapy. 2015 Feb;59(2):1384.
  5. Alffenaar J-WC, Gumbo T, Aarnoutse RE. Acquired Drug Resistance: We Can Do More Than We Think!. Clinical Infectious Diseases. 2015 Mar 15;60(6):969-70.
  6. Bahri P, Dodoo AN, Edwards BD, Edwards IR, Fermont I, Hagemann U, Hartigan-Go K, Hugman B, Mol PG. The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance. Drug Safety. 2015 Jul;38(7):621-627.
  7. Berhe DF, Juhlin K, Star K, Beyene KG, Dheda M, Haaijer-Ruskamp FM, Taxis K, Mol PG.Adverse Drug Reaction reports for cardiometabolic drugs from sub-Saharan Africa: a study in VigiBase. Tropical Medicine & International Health. 2015 Jun;20(6):797-806.
  8. Berm EJ, Hak E, Postma M, Boshuisen M, Breuning L, Brouwers JR, Dhondt T, Jansen PA, Kok RM, Maring JG, van Marum R, Mulder H, Voshaar RC, Risselada AJ, Venema H, Vleugel L, Wilffert B. Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial). TRIALS. 2015 Jan 31;16(1). 37.
  9. Berm EJJ, Paardekooper J, Brummel-Mulder E, Hak E, Wilffert B, Maring JG. A simple dried blood spot method for therapeutic drug monitoring of the tricyclic antidepressants amitriptyline, nortriptyline, imipramine, clomipramine, and their active metabolites using LC-MS/MS. Talanta. 2015 Mar 1;134:165-172.
  10. Beyer AR, Fasolo B, de Graeff PA, Hillege HL. Risk Attitudes and Personality Traits Predict Perceptions of Benefits and Risks for Medicinal Products: A Field Study of European Medical Assessors. Value in Health. 2015 Jan;18(1):91-99.
  11. Bolhuis MS, Tiberi S, Sotgiu G, De Lorenzo S, Kosterink JG, van der Werf TS, Migliori GB, Alffenaar JW. Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study. Eur Respir J. 2015 Oct;46(4):1205-7.
  12. Buurman DJ, Maurer JM, Keizer RJ, Kosterink JGW, Dijkstra G. Letter: infliximab therapy for patients with inflammatory bowel disease - some unanswered questions. Authors' reply. ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2015 Nov;42(9):1134-1134.
  13. Buurman DJ, Maurer JM, Keizer RJ, Kosterink JGW, Dijkstra G. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice. ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2015 Sep;42(5):529-539.
  14. Daskapan A, de Lange WC, Akkerman OW, Kosterink JG, van der Werf TS, Stienstra Y, Alffenaar JW. The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. European Respiratory Journal. 2015 Feb;45(2):569-571.
  15. Daskapan A, Stienstra Y, Akkerman OW, de Lange WC, Kosterink JG, van der Werf TS, Alffenaar JW. The Never Ending Struggle Against Development of Drug Resistance. Clinical Infectious Diseases. 2015 Jul 1;61(1):137-138.
  16. Daud AN, Bergman JE, Bakker MK, Wang H, Kerstjens-Frederikse WS, de Walle HE, Groen H, Bos JH, Hak E, Wilffert B. P-Glycoprotein-Mediated Drug Interactions in Pregnancy and Changes in the Risk of Congenital Anomalies: A Case-Reference Study. Drug Safety. 2015 Jul 2;38(7):651-659.
  17. de Vries FM, Denig P, Vegter S, Bos HJ, Postma MJ, Hak E. Does a cardiovascular event change adherence to statin treatment in patients with type 2 diabetes? A matched cohort design. Current Medical Research and Opinion. 2015 Apr;31(4):595-602.
  18. de Vries FM, Voorham J, Hak E, Denig P. Adherence to standard-dose or low-dose statin treatment and LDL-cholesterol response in type 2 diabetes patients. Current Medical Research and Opinion. 2015 Sep 11;31(12):2197-2206.
  19. de Vries ST, de Vries FM, Dekker T, Haaijer-Ruskamp FM, de Zeeuw D, Ranchor AV, Denig P. The Role of Patients' Age on Their Preferences for Choosing Additional Blood Pressure-Lowering Drugs: A Discrete Choice Experiment in Patients with Diabetes. Current Medical Research and Opinion 2015 Oct 7;10(10). 0139755.
  20. de Zeeuw D, Anzalone DA, Cain VA, Cressman MD, Heerspink HJ, Molitoris BA, Monyak JT, Parving HH, Remuzzi G, Sowers JR, Vidt DG. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes & Endocrinology. 2015 Mar;3(3):181-190.
  21. de Zeeuw D, Bekker P, Henkel E, Hasslacher C, Gouni-Berthold I, Mehling H, Potarca A, Tesar V, Heerspink HJ, Schall TJ; CCX140-B Diabetic Nephropathy Study Group. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes & Endocrinology. 2015 Sep;3(9):687-696.
  22. de Zeeuw D, Meyer C. The paradox created by commenting on large clinical trial results. Diabetes obesity & metabolism. 2015 Jan;17(1):1-2.
  23. Dekkers BG, Naeimi S, Bos IS, Menzen MH, Halayko AJ, Hashjin GS, Meurs H.L-Thyroxine promotes a proliferative airway smooth muscle phenotype in the presence of TGF-β1. American Journal of Physiology - Lung Cellular and Molecular Physiology. 2015 Feb 1;308(3):L301-L306.
  24. den Hollander MW, Bensch F, Glaudemans AW, Oude Munnink TH, Enting RH, den Dunnen WF, Heesters MA, Kruyt FA, Lub-de Hooge MN, Cees de Groot J, Pearlberg J, Gietema JA, de Vries EG, Walenkamp AM.TGF-beta Antibody Uptake in Recurrent High-Grade Glioma Imaged with Zr-89-Fresolimumab PET. Journal of Nuclear Medicine. 2015 Sep;56(9):1310-1314.
  25. Denig P. Adequaat starten, aanpassen én stoppen van medicatie. Pharm Weekbl 2015;150:22-24.
  26. Dijkmans AC, Wilms EB, Kamerling IM, Birkhoff W, Ortiz-Zacarías NV, van Nieuwkoop C, Verbrugh HA, Touw DJ. Colistin: Revival of an Old Polymyxin Antibiotic. Therapeutic Drug Monitoring. 2015 Aug;37(4):419-427.
  27. Dijkstra JA, Alsaad NSI, Hateren KV, Greijdanus B, Touw DJ, Alffenaar J-WC. Quantification of co-trimoxazole in serum and plasma using MS/MS. Bioanalysis. 2015 Nov 1;7(21):2741-2749.
  28. Dijkstra JA, van Altena R, Akkerman OW, de Lange WC, Proost JH, van der Werf TS, Kosterink JG, Alffenaar JW.Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis. International journal of antimicrobial agents. 2015 Sep;46(3):332-337.
  29. Dik JW, Hendrix R, Friedrich AW, Luttjeboer J, Panday PN, Wilting KR, Lo-Ten-Foe JR, Postma MJ, Sinha B. Cost-Minimization Model of a Multidisciplinary Antibiotic Stewardship Team Based on a Successful Implementation on a Urology Ward of an Academic Hospital. PLoS ONE. 2015 May 8;10(5). 0126106.
  30. Dik JW, Hendrix R, Lo-Ten-Foe JR, Wilting KR, Panday PN, van Gemert-Pijnen LE, Leliveld AM, van der Palen J, Friedrich AW, Sinha B.Automatic day-2 intervention by a multidisciplinary antimicrobial stewardship-team leads to multiple positive effects. Frontiers in Microbiology. 2015 Jun 3;6(546).
  31. Dugbartey GJ, Bouma HR, Strijkstra AM, Boerema AS, Henning RH. Induction of a Torpor-Like State by 5 '-AMP Does Not Depend on H2S Production. Plos one. 2015 Aug 21;10(8). 0136113.
  32. Dugbartey GJ, Talaei F, Houwertjes MC, Goris M, Epema AH, Bouma HR, Henning RH. Dopamine treatment attenuates acute kidney injury in a rat model of deep hypothermia and rewarming - The role of renal H2S-producing enzymes. European Journal of Pharmacology. 2015 Dec 15;769:225-233.
  33. Duncker DJ, Bakkers J, Brundel BJ, Robbins J, Tardiff JC, Carrier L. Animal and in silico models for the study of sarcomeric cardiomyopathies. Cardiovascular Research. 2015 Apr 1;105(4):439-448.
  34. Encalada Ventura MA, Span LF, van den Heuvel ER, Groothuis GM, Alffenaar JW. Influence of inflammation on voriconazole metabolism. Antimicrob Agents Chemother. 2015 May;59(5):2942-3.
  35. Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Weiss R, Rosenstock J, Capuano G, Desai M, Shaw W, Vercruysse F, Meininger G, Neal B. Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. Diabetes Ther. 2015 Sep;6(3):289-302.
  36. Golestani R, Mirfeizi L, Zeebregts CJ, Westra J, de Haas HJ, Glaudemans AW, Koole M, Luurtsema G, Tio RA, Dierckx RA, Boersma HH, Elsinga PH, Slart RH.Feasibility of [18F]-RGD for ex vivo imaging of atherosclerosis in detection of αvβ3 integrin expression. JOURNAL OF NUCLEAR CARDIOLOGY. 2015 Feb 20;20(1):39.
  37. Grams ME, Sang Y, Ballew SH, Gansevoort RT, Kimm H, Kovesdy CP, Naimark D, Oien C, Smith DH, Coresh J, Sarnak MJ, Stengel B, Tonelli M; CKD Prognosis Consortium. A Meta-analysis of the Association of Estimated GFR, Albuminuria, Age, Race, and Sex With Acute Kidney Injury. American Journal of Kidney Diseases. 2015 Oct;66(4):591-601.
  38. Helmons PJ, Coates CR, Kosterink JGW, Daniels CE. Decision support at the point of prescribing to increase formulary adherence. American Journal of Health-System Pharmacy. 2015 Mar 1;72(5):408-413.
  39. Helmons PJ, Suijkerbuijk BO, Nannan Panday P, Kosterink JGW. Drug-drug interaction checking assisted by clinical decision support: a return on investment analysis. Journal of the American Medical Informatics Association. 2015 Jul;22(4):764-772.
  40. Helmons PJ, Suijkerbuijk BO, Nannan Panday PV, Kosterink JGW. Doing the right things and doing things right: inpatient drug surveillance assisted by clinical decision support. European Journal of Hospital Pharmacy: Science and Practice. 2015 Jul;22(4):236-242.
  41. Hofman S, Bolhuis MS, Koster RA, Akkerman OW, van Assen S, Stove C, Alffenaar JW. Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples. Bioanalysis. 2015 Mar;7(4):481-495.
  42. Humalda JK, Lambers Heerspink HJ, Kwakernaak AJ, Slagman MC, Waanders F, Vervloet MG, Ter Wee PM, Navis G, de Borst MH; NIGRAM Consortium. Fibroblast Growth Factor 23 and the Antiproteinuric Response to Dietary Sodium Restriction During Renin-Angiotensin-Aldosterone System Blockade. American Journal of Kidney Diseases. 2015 Feb;65(2):259-266.
  43. Huong-Thao Nguyen U, Tuan-Dung Nguyen NV, van den Heuvel ER, Haaijer-Ruskamp FM, Taxis K. Medication Errors in Vietnamese Hospitals: Prevalence, Potential Outcome and Associated Factors. PLoS ONE. 2015 Sep 18;10(9). 0138284.
  44. James MT, Grams ME, Woodward M, Elley CR, Green JA, Wheeler DC, de Jong P, Gansevoort RT, Levey AS, Warnock DG, Sarnak MJ; CKD Prognosis Consortium. A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury. American Journal of Kidney Diseases. 2015 Oct;66(4):602-612.
  45. Jun M, Turin TC, Woodward M, Perkovic V, Lambers Heerspink HJ, Manns BJ, Tonelli M, Hemmelgarn BR. Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis. Journal of the American Society of Nephrology. 2015 Sep;26(9):2289-2302.
  46. Kent S, Schlackow I, Lozano-Kühne J, Reith C, Emberson J, Haynes R, Gray A, Cass A, Baigent C, Landray MJ, Herrington W, Mihaylova B; SHARP Collaborative Group. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?. Bmc nephrology. 2015;16:65.
  47. Keyzer CA, Lambers-Heerspink HJ, Joosten MM, Deetman PE, Gansevoort RT, Navis G, Kema IP, de Zeeuw D, Bakker SJ, de Borst MH; PREVEND Study Group. Plasma Vitamin D Level and Change in Albuminuria and eGFR According to Sodium Intake. Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2119-27.
  48. Kohan DE, Lambers Heerspink HJ, Coll B, Andress D, Brennan JJ, Kitzman DW, Correa-Rotter R, Makino H, Perkovic V, Hou FF, Remuzzi G, Tobe SW, Toto R, Parving HH, de Zeeuw D.Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. Clinical Journal of the American Society of Nephrology. 2015 Sep 4;10(9):1568-74.
  49. Koster RA, Alffenaar JW, Botma R, Greijdanus B, Uges DR, Kosterink JG, Touw DJ. The relation of the number of hydrogen-bond acceptors with recoveries of immunosuppressants in DBS analysis. Bioanalysis. 2015 Aug 1;7(14):1717-1722.
  50. Koster RA, Alffenaar J-WC, Botma R, Greijdanus B, Touw DJ, Uges DRA et al. What is the right blood hematocrit preparation procedure for standards and quality control samples for dried blood spot analysis?. Bioanalysis. 2015;7(3):345-351.
  51. Koster RA, Botma R, Greijdanus B, Uges DR, Kosterink JG, Touw DJ, Alffenaar JW. The performance of five different dried blood spot cards for the analysis of six immunosuppressants. Bioanalysis. 2015;7(10):1225-1235.
  52. Koster RA, Greijdanus B, Alffenaar J-WC, Touw DJ. Dried blood spot analysis of creatinine with LC-MS/MS in addition to immunosuppressants analysis. Analytical and Bioanalytical Chemistry. 2015 Feb;407(6):1585-1594.
  53. Koster RA, Vereecke HEM, Greijdanus B, Touw DJ, Struys MMRF, Alffenaar JWC. Analysis of Remifentanil with Liquid Chromatography-Tandem Mass Spectrometry and an Extensive Stability Investigation in EDTA Whole Blood and Acidified EDTA Plasma. Anesthesia and Analgesia. 2015 Jun;120(6):1235-1241.
  54. Kröpelin TF, de Zeeuw D, Andress DL, Bijlsma MJ, Persson F, Parving HH, Heerspink HJ. Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy. Clinical Journal of the American Society of Nephrology. 2015 Mar 6;10(3):410-416. 
  55. Lambers Heerspink H, Gansevoort RT. Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View. Clinical Journal of the American Society of Nephrology. 2015 Jun;10(6):1079-1088.
  56. Lambers Heerspink H, Gansevoort RT. Rebuttal of the Con View: Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD. Clinical Journal of the American Society of Nephrology. 2015 Jun;10(6):1099-1099.
  57. Lambers Heerspink HJ, Johnsson E, Gause-Nilsson I, Sjostrom C. Erratum to: Abstracts of the 51st Annual Meeting of the EASD, Stockholm 2015. 'Dapagliflozin reduces albuminuria on top of renin-angiotensin system blockade in hypertensive patients with diabetes' (vol 58, pg 1, 2015). Diabetologia. 2015 Dec;58(12):2901-2901.
  58. Lambers Heerspink HJ, Kropelin TF, Hoekman J, de Zeeuw D, Reducing Albuminuria Surrogate. Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis. Journal of the American Society of Nephrology. 2015 Aug;26(8):2055-2064.
  59. Lambers Heerspink HJ, Oberbauer R, Perco P, Heinzel A, Heinze G, Mayer G, Mayer B. Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine. Nephrology, Dialysis, Transplantation. 2015 Aug;30:105-112.
  60. Lamberts LE, Williams SP, Terwisscha van Scheltinga AG, Lub-de Hooge MN, Schröder CP, Gietema JA, Brouwers AH, de Vries EG. Antibody Positron Emission Tomography Imaging in Anticancer Drug Development. Journal of Clinical Oncology. 2015 May 1;33(13):1491-1504.
  61. Lanters EA, van Marion DM, Kik C, Steen H, Bogers AJ, Allessie MA, Brundel BJ, de Groot NM. HALT & REVERSE: Hsf1 activators lower cardiomyocyt damage; towards a novel approach to REVERSE atrial fibrillation. Journal of translational medicine. 2015;13(1):347.
  62. Lanters EAH, van Marion DMS, Steen H, de Groot NMS, Brundel BJJM. The future of atrial fibrillation therapy: intervention on heat shock proteins influencing electropathology is the next in line. Netherlands Heart Journal. 2015 Jun;23(6):327-333.
  63. Martono DP, Lub R, Heerspink HJL, Hak E, Wilffert B, Denig P. Predictors of response in initial users of metformin and sulphonylurea derivatives: a systematic review. Diabetic Medicine. 2015 Jul;32(7):853-864.
  64. Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, Jafar T, Jassal SK, Landman GW, Muntner P, Roderick P, Sairenchi T, Schöttker B, Shankar A, Shlipak M, Tonelli M, Townend J, van Zuilen A, Yamagishi K, Yamashita K, Gansevoort R, Sarnak M, Warnock DG, Woodward M, Ärnlöv J; CKD Prognosis Consortium. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes & Endocrinology. 2015 Jul;3(7):514-525. Available from: 10.1016/S2213-8587(15)00040-6
  65. Maurer JM, Schellekens RC, van Rieke HM, Wanke C, Iordanov V, Stellaard F, Wutzke KD, Dijkstra G, van der Zee M, Woerdenbag HJ, Frijlink HW, Kosterink JG. Gastrointestinal pH and Transit Time Profiling in Healthy Volunteers Using the IntelliCap System Confirms Ileo-Colonic Release of ColoPulse Tablets. PLoS ONE. 2015 Jul 15;10(7). 0129076.
  66. Meijering RA, Wiersma M, van Marion DM, Zhang D, Hoogstra-Berends F, Dijkhuis AJ, Schmidt M, Wieland T, Kampinga HH, Henning RH, Brundel BJ. RhoA Activation Sensitizes Cells to Proteotoxic Stimuli by Abrogating the HSF1-Dependent Heat Shock Response. PLoS ONE. 2015 Jul 21;10(7):e0133553.
  67. Meijering RAM, Henning RH, Brundel BJJM. Reviving the protein quality control system: Therapeutic target for cardiac disease in the elderly. TRENDS IN CARDIOVASCULAR MEDICINE. 2015 Apr;25(3):243-247.
  68. Mol PG, Arnardottir AH, Straus SM, de Graeff PA, Haaijer-Ruskamp FM, Quik EH, Krabbe PF, Denig P. Understanding drug preferences, different perspectives. British Journal of Clinical Pharmacology. 2015 Jun;79(6):978-987.
  69. Molitch ME, Adler AI, Flyvbjerg A, Nelson RG, So WY, Wanner C, Kasiske BL, Wheeler DC, de Zeeuw D, Mogensen CE. Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney International. 2015 Jan;87(1):20-30.
  70. Muskiet MHA, Tonneijck L, Smits MM, Kramer MHH, Lambers Heerspink H, van Raalte DH. Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. Lancet Diabetes & Endocrinology. 2015 May;3(5):367-381.
  71. Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K, Desai M, Shaw  W, Capuano G, Alba M, Jiang J, Vercruysse F, Meininger G, Matthews D; CANVAS Trial Collaborative Group. Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes. Diabetes Care. 2015 Mar;38(3):403-411.
  72. Nguyen HT, Nguyen TD, van den Heuvel ER, Haaijer-Ruskamp FM, Taxis K. Medication Errors in Vietnamese Hospitals: Prevalence, Potential Outcome and Associated Factors. PLoS One. 2015 Sep 18;10(9):e0138284.
  73. Nienhuis HH, Gaykema SB, Timmer-Bosscha H, Jalving M, Brouwers AH, Lub-de Hooge MN, van der Vegt B, Overmoyer B, de Vries EG, Schröder CP. Targeting breast cancer through its microenvironment: Current status of preclinical and clinical research in finding relevant targets. PHARMACOLOGY & THERAPEUTICS. 2015 Mar;147:63-79.
  74. Olde Engberink RH, Rorije NM, Lambers Heerspink HJ, De Zeeuw D, van den Born BJ, Vogt L. The blood pressure lowering potential of sulodexide - a systematic review and meta-analysis. Br J Clin Pharmacol. 2015 Dec;80(6):1245-53.
  75. Oosting SF, Brouwers AH, van Es SC, Nagengast WB, Oude Munnink TH, Lub-de Hooge MN, Hollema H, de Jong JR, de Jong IJ, de Haas S, Scherer SJ, Sluiter WJ, Dierckx RA, Bongaerts AH, Gietema JA, de Vries EG. 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. Journal of Nuclear Medicine. 2015 Jan;56(1):63-69.
  76. Pena MJ, de Zeeuw D, Mischak H, Jankowski J, Oberbauer R, Woloszczuk W, Benner J, Dallmann G, Mayer B, Mayer G, Rossing P, Lambers Heerspink HJ. Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes. Nephrology, Dialysis, Transplantation. 2015 Aug;30:86-95.
  77. Pena MJ, Heinzel A, Heinze G, Alkhalaf A, Bakker SJ, Nguyen TQ, Goldschmeding R, Bilo HJ, Perco P, Mayer B, de Zeeuw D, Lambers Heerspink HJ. A Panel of Novel Biomarkers Representing Different Disease Pathways Improves Prediction of Renal Function Decline in Type 2 Diabetes. PLoS ONE. 2015 May 14;10(5). 0120995.
  78. Pena MJ, Jankowski J, Heinze G, Kohl M, Heinzel A, Bakker SJ, Gansevoort RT, Rossing P, de Zeeuw D, Heerspink HJ, Jankowski V. Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes. J Hypertens. 2015 Oct;33(10):2123-32.
  79. Perwitasari DA, Atthobari J, Wilffert B. Pharmacogenetics of isoniazid-induced hepatotoxicity. Drug metabolism reviews. 2015;47(2):222-228.
  80. Posma RA, Lexis CP, Lipsic E, Nijsten MW, Damman K, Touw DJ, van Veldhuisen DJ, van der Harst P, van der Horst IC. Effect of Metformin on Renal Function After Primary Percutaneous Coronary Intervention in Patients Without Diabetes Presenting with ST-elevation Myocardial Infarction: Data from the GIPS-III Trial. Cardiovasc Drugs Ther. 2015 Oct;29(5):451-9.
  81. Rabelink TJ, de Zeeuw D. The glycocalyx-linking albuminuria with renal and cardiovascular disease. NATURE REVIEWS NEPHROLOGY. 2015 Nov;11(11):667-676.
  82. Radawski C, Morrato E, Hornbuckle K, Bahri P, Smith M, Juhaeri J, Mol P, Levitan B, Huang HY, Coplan P, Li H; BRACE Special Interest Group. Benefit-Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist. Pharmacoepidemiol Drug Saf. 2015 Dec;24(12):1233-40.
  83. Robijns K, Boone NW, Kuypers AWHM, Jansen RTP, Neef C, Touw DJ. A Multilaboratory Commutability Evaluation of Proficiency Testing Material for Carbamazepine and Valproic Acid: A Study Within the Framework of the Dutch Calibration 2000 Project. Therapeutic Drug Monitoring. 2015 Aug;37(4):445-450.
  84. Roscioni SS, Lambers Heerspink H. New nonabsorbable potassium-exchange resins in hyperkalaemia. NATURE REVIEWS NEPHROLOGY. 2015 Apr;11(4):205-206.
  85. Schievink B, de Zeeuw D, Parving H-H, Rossing P, Lambers Heerspink H. The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. British Journal of Clinical Pharmacology. 2015 Oct;80(4):678-686.
  86. Schievink B, Mol PGM, Heerspink H. Surrogate endpoints in clinical trials of chronic kidney disease progression: moving from single to multiple risk marker response scores. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION. 2015 Sep 1.
  87. Schutte E, Gansevoort RT, Benner J, Lutgers HL, Lambers Heerspink HJ. Will the future lie in multitude? A critical appraisal of biomarker panel studies on prediction of diabetic kidney disease progression. Nephrology, Dialysis, Transplantation. 2015 Aug;30:96-104.
  88. Schutte E, Lambers Heerspink HJ, Lutgers HL, Bakker SJ, Vart P, Wolffenbuttel BH, Umanath K, Lewis JB, de Zeeuw D, Gansevoort RT. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial). American Journal of Kidney Diseases. 2015 Sep;66(3):450-458.
  89. Setiawan D, Luttjeboer J, Westra TA, Wilschut JC, Suwantika AA, Daemen T, Atthobari J, Wilffert B, Postma MJ. The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective. Expert review of vaccines. 2015 Apr 1;14(4):589-604.
  90. Sotgiu G, Alffenaar JW, Centis R, D'Ambrosio L, Spanevello A, Piana A, Migliori GB. Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment. International Journal of Infectious Diseases. 2015 Mar;32:101-104.
  91. Strijbos E, Coenradie S, Touw DJ, Aerden LAM. High-dose methylprednisolone for multiple sclerosis during lactation: Concentrations in breast milk. Multiple Sclerosis. 2015 May 4;21(6):797-798.
  92. Sturkenboom MG, Mulder LW, de Jager A, van Altena R, Aarnoutse RE, de Lange WC, Proost JH, Kosterink JG, van der Werf TS, Alffenaar JW. Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis. Antimicrobial Agents and Chemotherapy. 2015 Aug;59(8):4907-4913.
  93. Sturkenboom MG, van der Lijke H, Jongedijk EM, Kok WT, Greijdanus B, Uges DR, Alffenaar JW. Quantification of isoniazid, pyrazinamide and ethambutol in serum using liquid chromatography-tandem mass spectrometry. Journal of Applied Bioanalysis. 2015 Jul 15;1(3):89-98.
  94. Sturkenboom MGG, Akkerman OW, Bolhuis MS, de Lange WCM, van der Werf TS, Alffenaar J-WC. Adequate Design of Pharmacokinetic-Pharmacodynamic Studies Will Help Optimize Tuberculosis Treatment for the Future. Antimicrobial Agents and Chemotherapy. 2015 Apr;59(4):2474-2474.
  95. Sundström J, Arima H, Jackson R, Turnbull F, Rahimi K, Chalmers J, Woodward M, Neal B; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Annals of Internal Medicine. 2015 Feb 3;162(3):184-91.
  96. Ter Horst PG, Proost JH, Smit JP, Vries MT, de Jong-van de Berg LT, Wilffert B. Pharmacokinetics of clomipramine during pregnancy. Eur J Clin Pharmacol. 2015 Dec;71(12):1493-500.
  97. ter Laak MA, Roos C, Touw DJ, van Hattum PR, Kwee A, Lotgering FK, Mol BW, van Pampus MG, Porath MM, Spaanderman ME, van der Post JA, Papatsonis DN, van 't Veer NE. Pharmacokinetics of nifedipine slow-release tablets during sustained tocolysis. International Journal of clinical Pharmacology and Therapeutics. 2015 Jan;53(1):84-91.
  98. Ter Weele EJ, Terwisscha van Scheltinga AG, Kosterink JG, Pot L, Vedelaar SR, Lamberts LE, Williams SP, Lub-de Hooge MN, de Vries EG. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with Zr-89 and IRDye 800CW in mice bearing human pancreatic tumor xenografts. Oncotarget. 2015 Dec 8;6(39):42081-42090.
  99. Teuwen CP, Ramdjan TT, Götte M, Brundel BJ, Evertz R, Vriend JW, Molhoek SG, Dorman HG, van Opstal JM, Konings TC, van der Voort P, Delacretaz E, Houck C, Yaksh A, Jansz LJ, Witsenburg M, Roos-Hesselink JW, Triedman JK, Bogers AJ, de Groot NM. Time Course of Atrial Fibrillation in Patients With Congenital Heart Defects. Circ Arrhythm Electrophysiol. 2015 Oct;8(5):1065-72.
  100. Toering TJ, van der Graaf AM, Visser FW, Buikema H, Navis G, Faas MM, Lely AT. Gender differences in response to acute and chronic angiotensin II infusion: a translational approach. Physiological Reports. 2015 Jul;3(7). E12434.
  101. van Ballegooijen AJ, Gansevoort RT, Lambers-Heerspink HJ, de Zeeuw D, Visser M, Brouwer IA, Kema IP, de Borst MH, Bakker SJ, Joosten MM. Plasma 1,25-Dihydroxyvitamin D and the Risk of Developing Hypertension: The Prevention of Renal and Vascular End-Stage Disease Study. HYPERTENSION. 2015 Sep;66(3):563-570.
  102. van der Elst KC, Brouwers CH, van den Heuvel ER, van Wanrooy MJ, Uges DR, van der Werf TS, Kosterink JG, Span LF, Alffenaar JW. Subtherapeutic Posaconazole Exposure and Treatment Outcome in Patients With Invasive Fungal Disease. Therapeutic Drug Monitoring. 2015 Dec;37(6):766-71.
  103. van der Meer DH, Wieringa A, Wegner I, Wilffert B, Ter Horst PGJ. Lactation studies of anticonvulsants: A quality review. British Journal of Clinical Pharmacology. 2015;79(4):558-565.
  104. van der Paardt AF, Wilffert B, Akkerman OW, de Lange WC, van Soolingen D, Sinha B, van der Werf TS, Kosterink JG, Alffenaar JW. Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis. European Respiratory Journal. 2015 Aug;46(2):444-455.
  105. van Doorn E, Hak E, Wilffert B. National differences in requirements for ethical and competent authority approval for a multinational vaccine trial under the EU directive 2001/20/EC. Vaccines. 2015 Apr 14;3(2):263-292.
  106. van Gerwen M, Scheper H, Touw DJ, van Nieuwkoop C. Life-threatening acute lung injury after gamma butyrolactone ingestion. Netherlands Journal of Medicine. 2015 Mar;73(3):133-135.
  107. van Maarseveen E, Man WH, Proost J, Neef C, Touw D. Chronopharmacokinetics of once daily dosed aminoglycosides in hospitalized infectious patients. International Journal of Clinical Pharmacy. 2015 Apr;37(2):342-347.
  108. van Tilborgh-de Jong AJW, Wiersum-Osselton JC, Touw DJ, Schipperus MR. Presence of medication taken by blood donors in plasma for transfusion. Vox Sanguinis. 2015 May 1;108(4):323-327.
  109. van Velzen AJ, Uges JW, Le Brun PP, Shahbabai P, Touw DJ, Heijerman HG. The influence of breathing mode on tobramycin serum levels using the I-neb AAD system in adults with cystic fibrosis. J Cyst Fibros. 2015 Nov;14(6):748-54.
  110. Van Wagoner DR, Piccini JP, Albert CM, Anderson ME, Benjamin EJ, Brundel B, Califf RM, Calkins H, Chen PS, Chiamvimonvat N, Darbar D, Eckhardt LL, Ellinor PT, Exner DV, Fogel RI, Gillis AM, Healey J, Hohnloser SH, Kamel H, Lathrop DA, Lip GY, Mehra R, Narayan SM, Olgin J, Packer D, Peters NS, Roden DM, Ross HM, Sheldon R, Wehrens XH. Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on theTreatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. Heart Rhythm. 2015 Jan;12(1):E5-U37.
  111. van Wanrooy MJ, Proost JH, Rodgers MG, Zijlstra JG, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW. Limited-sampling strategies for anidulafungin in critically ill patients. Antimicrobial Agents and Chemotherapy. 2015 Feb 1;59(2):1177-1181.
  112. Vart P, Bakker SJ, Schöttker B, de Zeeuw D, Rothenbacher D, Brenner H, Heerspink HJ, Saum KU, Reijneveld SA, Bültmann U, Koenig W, Gansevoort RT. Relevance of correction for drift and day-to-day variation in cystatin C measurement: a post-hoc analysis of the PREVEND cohort, with independent replication in the ESTHER cohort. Clinical chemistry and laboratory medicine. 2015 Aug;53(9):1381-1390.
  113. Vavrincova-Yaghi D, Seelen MA, Kema IP, Deelman LE, van der Heuvel MC, Breukelman H, Van den Eynde BJ, Henning RH, van Goor H, Sandovici M. Early Posttransplant Tryptophan Metabolism Predicts Long-term Outcome of Human KidneyTransplantation. Transplantation. 2015 Aug;99(8):e97-104.
  114. Weldegiorgis M, de Zeeuw D, Lambers Heerspink HJ. Renal end points in clinical trials of kidney disease. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION. 2015 May;24(3):284-289.
  115. Ying A, Arima H, Czernichow S, Woodward M, Huxley R, Turnbull F, Perkovic V, Neal B. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials.Lancet. 2015 Mar 7;385(9971):867-874.
  116. Yska JP, van Roon EN, de Boer A, Leufkens HG, Wilffert B, de Heide LJ, de Vries F, Lalmohamed A. Remission of Type 2 Diabetes Mellitus in Patients After Different Types of Bariatric Surgery: A Population-Based Cohort Study in the United Kingdom. JAMA Surgery. 2015 Sep 30;1-8.